Organization
Rheumatology and Fraunhofer ITMP - Translational Medicine and Pharmacology
1 abstract
Abstract
ASSOCIATION BETWEEN ACHIEVEMENT OF LOW DISEASE ACTIVITY OR REMISSION WITH IMPROVEMENT IN QUALITY OF LIFE IN UPADACITINIB-TREATED PATIENTS IN THE PHASE 3 SELECT-PsA 1 AND 2 STUDIESOrg: AbbVie Inc., North Chicago, IL, Rheumatology and Fraunhofer ITMP - Translational Medicine and Pharmacology, AbbVie Deutschland GmbH & Co. KG, Griffith University, Rheumatology Research Unit,